Sterling banner image2

About Us

Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO), with 50 years’ experience in small molecule API development and manufacturing services. In April 2021 Sterling acquired ADC Bio, a UK based biotechnology company specialising in antibody drug conjugates and bioconjugation. Together, as Sterling Pharma Solutions, the teams have developed an integrated service offering for existing and potential customers, which combines ADC Bio’s expertise with Sterling’s high potency small molecule expertise.

Sterling has four facilities employing more than 800 people: its HQ in Dudley, Northumberland, UK; a dedicated bioconjugation and ADCs facility in Deeside, North Wales, UK; and two sites in the US, in Cary, North Carolina and Germantown, Wisconsin.

External Links

Passport Stamp for World ADC San Diego 2022

Passport 2022 SD (11)

Team Members

Colin-McKee

Colin McKee

Head of Technical Services, ADC Bio

Sara-Jenkins

Sara Jenkins

ADC Commercial Manager

John-Vu

John Vu

Business Development Director

David-Molyneux

David Molyneux

Business Development Director

Nick

Nick Hoy

Business Development Director

Lennart

Lennart Niehues

Business Development Director

Richard Cartwright

Richard Cartwright

QC Manager

stewrd

Stewart Mitchell

EVP/Site Head Deeside